Elucidating the precise pharmacological mechanism of motion (MOA) of naturally developing compounds could be tough. Even though Tarselli et al. (60) made the very first de novo artificial pathway to conolidine and showcased that this naturally transpiring compound proficiently suppresses responses to equally chemically induced and inflammation-deri